Medical Tidbits, Medical Marijuana, Inc.’s HempMeds Brasil™ Product RSHO™ Approved by Brazilian Government for Fourth Indication as a Prescription for Import: Cancer

Marijuana is used to treat epilepsy

EU Medical Marijuana, Inc. (OTC Pink: MJNA) is proud to announce to shareholders and the public that the Brazilian government has approved its hemp cannabidiol (CBD) oil product Real Scientific Hemp Oil™ (RSHO™) from HempMeds Brasil ™ for a fourth indication for import as a prescription medication for the treatment of cancer.

The first three indications approved for HempMeds Brasil ™ to import are: epilepsy , Parkinson’s disease and chronic pain . read more

Mylan Launches Generic Apresoline® Injection

HERTFORDSHIRE, England and PITTSBURGH, May 5, 2016 /PRNewswire/ — Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Hydralazine Hydrochloride Injection USP, 20 mg/mL, which is a generic version of Novartis’ Apresoline Injection, 20 mg/mL. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is used for the treatment of severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. read more

New Data Further Support Medtronic Leadership in Leadless Pacing at Heart Rhythm 2016

Medtronic plc (NYSE:MDT) today announced clinical results highlighting the strong safety and performance profile of the miniaturized Micra® Transcatheter Pacing System (TPS) at Heart Rhythm 2016, the Heart Rhythm Society’s 37th Annual Scientific Sessions in San Francisco. read more

Akili Interactive Labs Opens Enrollment for Pivotal Trial of Novel ADHD Treatment

Large-scale trial designed to validate digital medicine treatment for children with ADHD

BOSTON–(BUSINESS WIRE)– Akili Interactive Labs, Inc. (“Akili”), a company developing a novel, non-pharmacological technology for cognitive disorders, today announced open enrollment for its pivotal STARS-ADHD trial. The trial will evaluate the safety and efficacy of the company’s proprietary platform, Project: EVO, for the treatment of children with Attention Deficit Hyperactivity Disorder (ADHD). This large-scale pivotal trial marks an important inflection point in the advancement of digital medicine as a clinically-validated treatment for diagnosed patient populations.  read more

Novaliq Announces Last Patient Enrolled in Phase 2 Clinical Trial of CyclASol® for the Treatment of Moderate to Severe Dry Eye Disease

HEIDELBERG, Germany–(BUSINESS WIRE)–Novaliq GmbH, a pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, announced today the completion of enrollment in its Phase 2 clinical trial that is evaluating the safety, efficacy and tolerability of CyclASol® for the treatment of moderate to severe dry eye disease (DED). CyclASol is a clear, preservative-free ophthalmic solution of cyclosporine A formulated using Novaliq’s proprietory EyeSol® technology.  read more

ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma    

PRNewswire/ — ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) today announced that the Company has received approval from regulatory authorities in Canada, the United Kingdom and the Netherlands to initiate the ICT-107 Phase 3 registration trial in patients with newly diagnosed glioblastoma. Patient screening is anticipated to commence shortly and the first clinical supplies could be manufactured for qualifying patients in Canada and Europe in the third quarter of 2016.  The Company also is near to completing interactions with regulatory authorities in six other European countries and currently expects approval of those clinical trial applications in June 2016, with patient screening to begin in the third quarter of 2016. read more

Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease Finland Chosen for First-Ever Study to Evaluate the Potential of Blocking IL-15 in Celiac Disease

PRNewswire/ — Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing immune-mediated diseases, announced that it has dosed the first patient in its Phase 2 clinical study for AMG 714 in celiac disease. AMG 714 is an investigational anti-IL-15 monoclonal antibody being studied for the treatment of gluten-free diet non-responsive celiac disease (NRCD) and refractory celiac disease Type II (RCD-II). The celiac disease study is being conducted by several expert academic medical centers in Tampere, Oulu, and Turku, Finland, a country where the incidence and understanding of celiac disease ranks among the highest in the world. read more

Complete Remission Rate of 90%: China-based CAR-T Cell Therapy Achieves Breakthrough Clinical Trial Results

PRNewswire/ — At the 2016 Haematogenic Immunity Summit held in Hangzhou from April 22 to 24, 2016, Professor Huang He from the First Affiliated Hospital of Zhejiang University presented on the results for ten clinical cases that used CAR-T cell therapy for the treatment of leukemia. This is the first time that the complete data set from the clinical trials was made publicly available. read more

TOLMAR Pharmaceuticals Announces That FDA Approval Has Been Received For ELIGARD (leuprolide acetate for injectable suspension)

PRNewswire/ — TOLMAR Pharmaceuticals, Inc., today announced that approval has been received from FDA for a label update for ELIGARD®, indicated for the palliative treatment of advanced prostate cancer. Stability studies demonstrated that, prior to mixing, ELIGARD may be stored at room temperature (59 – 86° F) for up to 8 weeks following removal from refrigeration. ELIGARD is the only LHRH (luteinizing hormone releasing hormone) agonist with the innovative, controlled-release ATRIGEL® Delivery System. read more

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.